Yuan Yuan, MD, PhD, medical oncologist at City of Hope, discusses an ongoing study on ipatasertib with chemotherapy and atezolizumab presented at the San Antonio Breast Cancer Symposium 2020.
Novel oral drugs have been in the spotlight in light of the pandemic, and an ongoing trial at City of Hope aims to assess the safety and efficacy of a combination of oral ipatasertib, oral chemotherapy, and IV atezolizumab in the treatment of metastatic triple-negative breast cancer. Yuan Yuan, MD, PhD, associate professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discusses the ongoing trial, which is being presented at the 2020 San Antonio Breast Cancer Symposium.
Transcript
Your poster presentation is a study of ipatasertib with chemotherapy and atezolizumab in mTNBC. What do you expect to see as the trial goes on?
So we started off the preclinical study. We tested the combination of carboplatin, which is our chemotherapy backbone in our trial. We started off the cell lines, we did mice models, so we did preclinical experiments before launching the phase I trial. In our study we had clearly showed synergy between carboplatin and ipatasertib, so our preclinical observations are very promising, especially PIK3CA-mutated tumors.
Currently, our trial is still ongoing. We have a total accrual goal of 40 patients, and this morning I actually got a summary that about 24 patients are being treated so far. We're still a bit early in evaluating the response rate, so hopefully by sometime next year, we'll have the results. Now, safety is a major focus of this phase I trial. We have not observed any concerning safety signals, so the good news is that the combination appears to be very well tolerated.
In the current clinical trial, we have 3 arms. Arm 1 is combining carboplatin with paclitaxel plus ipatasertib. Now, arm 2 is combining carboplatin alone with ipatasertib. Arm 3 is of strong interest, because we have now adopted adjuvant capecitabine as a standard care for patients who underwent neoadjuvant chemotherapy for newly diagnosed, early-stage, triple-negative breast cancer who did not achieve complete response after standard care chemotherapy. And if they have residual cancer, they're now a standard of care, which is offering a capecitabine for a total of 6 months or course of therapy.
Our study is really designed to understand is it safe to combine capecitabine, which is oral chemo—pretty old, but very effective—with oral ipatasertib and IV immune checkpoint inhibitor atezolizumab. So the whole idea is that we are adding the 2 oral agents, and then we can on top of that add an immune checkpoint inhibitor. So currently, we have enrolled 4 or 5 patients so far. Safety is pretty well tolerated, and it is too early for efficacy analysis. We're looking forward to identifying activity. Hopefully by sometime next year, we'll have the answer.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More